FDA approves controversial new drug designed to slow progression of ALS
The Food and Drug Administration on Thursday approved a controversial new drug designed to slow the progression of Lou Gehrig’s disease, a victory for patients and advocates despite limited evidence that the drug is effective. The drug, from Amylyx Pharmaceuticals of Massachusetts, joins just a handful of agency-approved drugs for the deadly neurodegenerative disease and …
FDA approves controversial new drug designed to slow progression of ALS Read More »